Cytomegalovirus infection in brain tumors: A potential new target for therapy?

OncoImmunology

Volumn 1, Issue 5, 2012, Pages 739-740

  Söderberg Nauclér, Cecilia ^a   Johnsen, John Inge ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anti viral treatment; Brain tumor; Cancer; COX 2; Cytomegalovirus; Immunotherapy

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GANCICLOVIR; NUCLEIC ACID; VALGANCICLOVIR; VIRUS PROTEIN;

ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CYTOMEGALOVIRUS INFECTION; DRUG TARGETING; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TUMOR CELL;

EID: 84873898135     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19441     Document Type: Article

References (10)

1. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002; 62:3347-50; PMID:12067971
2. Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest 2011; 121:4043-55; PMID:21946257; http://dx.doi.org/10.1172/JCI57147
3. Harkins LE, Matlaf LA, Soroceanu L, Klemm K, Britt WJ, Wang W, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae 2010; 1:8; PMID:21429243; http://dx.doi.org/10.1186/2042-4280-1-8
4. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res 2011; 157:193-203; PMID:21036194; http://dx.doi.org/10.1016/j.virusres.2010.10.026
5. Melnick M, Sedghizadeh PP, Allen CM, Jaskoll T. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: Cellspecific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. Exp Mol Pathol 2012; 92:118-25; PMID:22101257; http://dx.doi.org/10.1016/j.yexmp.2011.10.011
6. Johnsen JI, Baryawno N, Söderberg-Nauclér C. Is human cytomegalovirus a target in cancer therapy? Oncotarget 2011; 2:1329-38; PMID:22246171
7. Rahbar A, Orrego A, Stragliotto G, Peredo I, Dzabic M, Wolmer-Solberg N, et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of high prognostic value for time to tumour progression and survival. Herpesviridae 2011; 3:3; http://dx.doi.org/10.1186/2042-4280-3-3
8. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31-41; PMID:21144578; http://dx.doi.org/10.1016/S0140-6736(10)62110-1
9. Melnick M, Abichaker G, Htet K, Sedghizadeh P, Jaskoll T. Small molecule inhibitors of the host cell COX/AREG/EGFR/ERK pathway attenuate cytomegalovirus- induced pathogenesis. Exp Mol Pathol 2011; 91:400-10; PMID:21565184; http://dx.doi.org/10.1016/j.yexmp.2011.04.014
10. Effects of Valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomised, double-blind, proof-of-concept study.